Clinical Trials in Nashville

Showing 16221-16240 of 20,298 trials

A Study of BIND-014 Given to Patients With Advanced or Metastatic Cancer

NCT01300533

The goal of this Phase 1 clinical research study is to find the highest safe dose of BIND-014 that can be given in the treatment of patients with advanced or metastatic cancer.

Metastatic CancerCancerSolid Tumors

BIND Therapeutics58 participantsStarted Jan 2011

Scottsdale, Arizona, United States • Greenbrae, California, United States • Los Angeles, California, United States +3 more locations

COMPLETEDPhase 3< 1 mile

Efficacy and Safety of Alirocumab (SAR236553/REGN727) Versus Placebo on Top of Lipid-Modifying Therapy in Patients With Heterozygous Familial Hypercholesterolemia Not Adequately Controlled With Their Lipid-Modifying Therapy

NCT01623115

Alirocumab (SAR236553/REGN727) is a fully human monoclonal antibody that binds PCSK9 (proprotein convertase subtilisin/kexin type 9). Primary Objective of the study: To evaluate the effect of alirocumab on low-density lipoprotein cholesterol (LDL-C) levels after 24 weeks of treatment in comparison with placebo. Secondary Objectives: * To evaluate the effect of alirocumab in comparison with placebo on LDL-C at other time points * To evaluate the effects of alirocumab on other lipid parameters * To evaluate the safety and tolerability of alirocumab

Hypercholesterolemia

Sanofi486 participantsStarted Jul 2012

Bell Gardens, California, United States • Long Beach, California, United States • Los Angeles, California, United States +88 more locations

A Study of BIND-014 Given to Patients With Advanced or Metastatic Cancer

Efficacy and Safety of Alirocumab (SAR236553/REGN727) Versus Placebo on Top of Lipid-Modifying Therapy in Patients With Heterozygous Familial Hypercholesterolemia Not Adequately Controlled With Their Lipid-Modifying Therapy

Find Trials by Condition in Nashville

AqueSys Microfistula Implant in Refractory Glaucoma

Combination of Bevacizumab, Pertuzumab, and Sandostatin for Adv. Neuroendocrine Cancers

An Open-Label Study to Evaluate the Safety of NP101 in the Treatment of Acute Migraine Over 12 Months

A Multicenter Trial Comparing REMICADE (Infliximab) and Placebo in the Prevention of Recurrence in Crohn's Disease (CD) Patients Undergoing Surgical Resection Who Are at an Increased Risk of Recurrence

The Efficacy and Tolerability of NP101 Patch in the Treatment of Acute Migraine

An Open-Label Study to Evaluate the Safety of NP101 in the Treatment of Acute Migraine Over Twelve Months

Characterisation of 24-hour FEV1-time Profiles of Inhaled BI 1744 CL and Inhaled Foradil in Patients With Chronic Obstructive Pulmonary Disease

Abatacept and Cyclophosphamide Combination Therapy for Lupus Nephritis

Safety and Tolerability Trial of Inhaled Alpha1-Proteinase Inhibitor (Human), Hydrophobic Chromatography Process (Alpha-1 HC) in Subjects With Cystic Fibrosis

A Study of Administration of Peginterferon Alfa-2a [Pegasys] by Autoinjector Versus Pre-filled Syringe in Patients With Chronic Hepatitis C

Oral Treprostinil in Subjects With Pulmonary Hypertension Associated With Pulmonary Fibrosis

Minocycline for the Treatment of Decreased Mental Function in HIV-Infected Adults

Feasibility Testing of the Quality-monitoring Tool, Qdact, for the Palliative Care Research Cooperative

Selumetinib in Treating Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma

Org 24448 (Ampakine) for Cognitive Deficits in Schizophrenia

Immunosuppressive Medications for Participants in ITN005CT (NCT00014911)

NWP09 in Children With Attention Deficit Hyperactivity Disorder (ADHD)

TearLab Refractive Surgery Dry Eye Study